VTL

VGI Health TechnologyNSX:VTL Stock Report

Market Cap

AU$34.6m

7D

0%

1Y

n/a

Updated

20 Oct, 2021

Data

Company Financials
VTL fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health2/6
Dividends0/6

VTL Overview

VGI Health Technology Limited, a biotechnology company, engages in the research, development, distribution, and marketing of various health and therapeutic products, and technologies.

VGI Health Technology Competitors

Alphabet

NasdaqGS:GOOG.L

US$1.9t

Facebook

NasdaqGS:FB

US$958.6b

Snap

NYSE:SNAP

US$121.6b

Twitter

NYSE:TWTR

US$52.6b

Price History & Performance

Summary of all time highs, changes and price drops for VGI Health Technology
Historical stock prices
Current Share PriceAU$0.25
52 Week HighAU$0.15
52 Week LowAU$0.30
Beta0
1 Month Change31.58%
3 Month Change66.67%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO13.64%

Recent News & Updates

Shareholder Returns

VTLAU PharmaceuticalsAU Market
7D0%1.8%1.7%
1Yn/a5.8%20.2%

Return vs Industry: Insufficient data to determine how VTL performed against the Australian Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how VTL performed against the Australian Market.

Price Volatility

Is VTL's price volatile compared to industry and market?
VTL volatility
VTL Beta0
Industry Beta1.3
Market Beta1

Stable Share Price: Insufficient data to determine VTL's volatility over the past 3 months.

Volatility Over Time: Insufficient data to determine VTL's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2004n/aGlenn Tonghttps://vgiht.com

VGI Health Technology Limited, a biotechnology company, engages in the research, development, distribution, and marketing of various health and therapeutic products, and technologies. It offers drugs and wellbeing supplements. The company also develops nE1-Heart for treatment of hyperlipidaemia; and nE1-Elite that reduce delayed onset muscle soreness, enhance muscle recovery, and provide exercise endurance and maintenance of muscle power.

VGI Health Technology Fundamentals Summary

How do VGI Health Technology's earnings and revenue compare to its market cap?
VTL fundamental statistics
Market CapAU$34.56m
Earnings (TTM)-AU$3.90m
Revenue (TTM)n/a

0x

P/S Ratio

-8.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
VTL income statement (TTM)
RevenueAU$0
Cost of RevenueAU$13.97k
Gross Profit-AU$13.97k
ExpensesAU$3.89m
Earnings-AU$3.90m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.028
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio2.5%

How did VTL perform over the long term?

See historical performance and comparison

Valuation

Is VGI Health Technology undervalued compared to its fair value and its price relative to the market?

4.13x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate VTL's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate VTL's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: VTL is unprofitable, so we can't compare its PE Ratio to the Oceanic Pharmaceuticals industry average.

PE vs Market: VTL is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate VTL's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: VTL is overvalued based on its PB Ratio (4.1x) compared to the AU Pharmaceuticals industry average (3.5x).


Future Growth

How is VGI Health Technology forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

67.4%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as VGI Health Technology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has VGI Health Technology performed over the past 5 years?

85.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: VTL is currently unprofitable.

Growing Profit Margin: VTL is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: VTL is unprofitable, but has reduced losses over the past 5 years at a rate of 85.8% per year.

Accelerating Growth: Unable to compare VTL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: VTL is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.4%).


Return on Equity

High ROE: VTL has a negative Return on Equity (-46.67%), as it is currently unprofitable.


Financial Health

How is VGI Health Technology's financial position?


Financial Position Analysis

Short Term Liabilities: VTL's short term assets (A$339.3K) do not cover its short term liabilities (A$1.2M).

Long Term Liabilities: VTL has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: VTL's debt to equity ratio (2.5%) is considered satisfactory.

Reducing Debt: VTL's debt to equity ratio has increased from 0.01% to 2.5% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: VTL has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: VTL has less than a year of cash runway if free cash flow continues to grow at historical rates of 46.2% each year.


Dividend

What is VGI Health Technology current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate VTL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate VTL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if VTL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if VTL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of VTL's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average board tenure


CEO

Glenn Tong

no data

Tenure

AU$314,878

Compensation

Dr. Glenn Tong, FACID, serves as Chief Executive Officer and Managing Director of VGI Health Technology Limited (formerly known as Azure Health Technology Limited). He was Director of Azure Health Technolo...


CEO Compensation Analysis

Compensation vs Market: Glenn's total compensation ($USD235.42K) is about average for companies of similar size in the Australian market ($USD302.06K).

Compensation vs Earnings: Insufficient data to compare Glenn's compensation with company performance.


Board Members

Experienced Board: VTL's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: VTL only recently listed within the past 12 months.


Top Shareholders

Company Information

VGI Health Technology Limited's employee growth, exchange listings and data sources


Key Information

  • Name: VGI Health Technology Limited
  • Ticker: VTL
  • Exchange: NSX
  • Founded: 2004
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$34.562m
  • Shares outstanding: 138.25m
  • Website: https://vgiht.com

Location

  • VGI Health Technology Limited
  • 19-29 Martin Place
  • Suite 03
  • Sydney
  • New South Wales
  • 2003
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/20 07:05
End of Day Share Price2021/10/04 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.